Andrea Ficari

Oral corticosteroids (OCS) are widely used in the management of pediatric asthma exacerbations and recurrent wheezing. Despite their established efficacy, concerns about safety, optimal dosing, and appropriate clinical contexts persist. This narrative review synthesizes evidence from studies published between 2000 and 2025, focusing on the efficacy, safety, and clinical applications of OCS in children. Pharmacological data were also included from earlier literature. Evidence indicates that OCS remain essential for managing moderate-to-severe asthma exacerbations in school-age children. In preschool wheezing, their benefit is inconsistent and appears limited to selected subgroups, such as children with virus-associated wheezing or established asthma. Short courses and lower doses provide comparable efficacy with improved tolerability. Among the available molecules, dexamethasone has emerged as a promising alternative due to better palatability and adherence, while deflazacort shows comparable efficacy but requires further validation. The role of OCS in pediatric respiratory disease should be individualized, balancing efficacy and safety. Future studies should refine patient selection and evaluate alternative corticosteroid molecules to optimize therapeutic strategies. The online version contains supplementary material available at 10.1186/s13052-026-02204-x.

Invasive infections caused by Streptococcus pyogfenes (iGAS), commonly known as Group A Streptococcus, represent a significant public health concern due to their potential for rapid progression and life-threatening complications. Epidemiologically, invasive GAS infections exhibit a diverse global distribution, affecting individuals of all ages with varying predisposing factors. The pathogenesis of invasive GAS involves an array of virulence factors that contribute to tissue invasion, immune evasion, and systemic dissemination. In pediatrics, in the last few years, an increase in iGAS infections has been reported worldwide becoming a challenging disease to diagnose and treat promptly. This review highlights the current knowledge on pathogenesis, clinical presentations, and therapeutic approaches for iGAS in children.

Physical inactivity and sedentary habits are among the major risk factors for decreased physical and mental well-being. Since the onset of the COVID-19 pandemic, normal daily routines changed, including physical activity (PA) habits. The aim of this manuscript is to review the literature according to the PRISMA guidelines in order to analyze the changes in PA and exercise practice after the onset of the COVID-19 pandemic and its impact on the well-being of adolescents. A PubMed search was performed using the keywords “Exercise” [Mesh]) AND “COVID-19” [Mesh], and filters to limit the research to pertain to adolescents (13–18 years) and English reports. Out of the search, 15 reports met the criteria for inclusion in the study. The main findings outlined a global decrease in PA levels associated with decreased well-being levels, modified eating habits and leisure time activity, and increased obesity, anxiety, and depression among adolescents. PA is a significant health determinant and should be improved through the awareness of the benefits of regular PA and of the risks of sedentary behavior, as well as through support from family, friends, and teachers. Providing PA at school, as a part of the academic program, increasing the availability of equipment and facilities, and promoting at-home PA options are suggested as support for increasing PA in all countries and settings.

Background: Varicella is considered a mild and self-limiting disease, but, in some cases, it may complicate and require hospitalization. Antibiotics are not the first line therapy but in some cases are prescribed either for the management of varicella-related complications or as a preventive strategy. Aim of this study is to analyze the rate and the patterns of antibiotics used in pediatric patients hospitalized for varicella as well as the relative costs in order to increase insights in antibiotic use in varicella. Methods: Patients less than 18 years hospitalized for varicella at the Bambino Gesù Children’s IRCCS Hospital in Rome, Italy, from the 1^st of November 2005 to the 1^st of November 2021 entered the study. Retrospective data were collected from the hospital's database electronic medical records. The rate, the patterns and the costs of antibiotics used were considered. Results: According to the inclusion criteria, we enrolled 810 patients, with a median age of 2.4 years. Out of them, 345 patients (42.6%) underwent antibiotic therapy, of which 307 for a complication (90.0%) and the other 10.0%, antibiotic for the fear of developing complications. The cost for varicella hospitalizations was EUR 2,928,749 (median cost EUR 2689). As for antibiotic therapy, it represented the 5.9% of the total cost (EUR 174,527), with a median cost of EUR 198.8. The cost in patients who underwent antibiotic therapy was significantly higher than in those who did not (p-value < 0.0001), as well as the hospitalization length (p-value < 0.0001). The most commonly prescribed antibiotics were Amoxicillin-clavulanate and Ceftriaxone, which represented the 36.0% and 25.0% of all antibiotic prescription, respectively. Antibiotics may negatively affect the economic cost of hospitalization and the prescription is not always in accordance to guidelines, with potential important repercussions on the development of antimicrobial resistance. Actually, resistance to antibiotics is considered a major risk to the future health of the world population as it may lead to longer hospital stay, increased risk of mortality, health care costs and treatment failures. Conclusion: Strategies to reduce economical cost, hospitalization length and antimicrobial resistance include ensuring appropriate prescription and administration of empiric antibiotics as well as reducing the circulation of preventable infectious diseases through immunization.